Strengthening this result, the opposite alterations, CDKN1B deletions (0.2% in metastases vs. 0.1% in local disease, p = 0.09) and mutations (1.9% in metastases vs. 1.1% in local disease, p = 0.05), trend toward significant enrichment in metastatic tumors. The gene discussed is CDKN1B; the disease is metastatic neoplasm.